Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Julio Fernandez-Banet"'
Autor:
Zhengyan Kan, Ying Ding, Jinho Kim, Hae Hyun Jung, Woosung Chung, Samir Lal, Soonweng Cho, Julio Fernandez-Banet, Se Kyung Lee, Seok Won Kim, Jeong Eon Lee, Yoon-La Choi, Shibing Deng, Ji-Yeon Kim, Jin Seok Ahn, Ying Sha, Xinmeng Jasmine Mu, Jae-Yong Nam, Young-Hyuck Im, Soohyeon Lee, Woong-Yang Park, Seok Jin Nam, Yeon Hee Park
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
While breast cancer incidence in the Asia Pacific region is rising, the molecular basis remains poorly characterized. Here the authors perform genomic screening of 187 Korean breast cancer patients and find differences in molecular subtype distributi
Externí odkaz:
https://doaj.org/article/389b15f6241d433099ba837bc4efcf72
Autor:
Jill Hallin, Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis, Lars D. Engstrom, Jade Laguer, James Medwid, Darin Vanderpool, Ella Lifset, David Trinh, Natalie Hoffman, Xiaolun Wang, J. David Lawson, Robin J. Gunn, Christopher R. Smith, Nicole C. Thomas, Matthew Martinson, Alex Bergstrom, Francis Sullivan, Karyn Bouhana, Shannon Winski, Leo He, Julio Fernandez-Banet, Adam Pavlicek, Jacob R. Haling, Lisa Rahbaek, Matthew A. Marx, Peter Olson, James G. Christensen
Publikováno v:
Nature Medicine. 28:2171-2182
Autor:
James G. Christensen, Peter Olson, Pasi A. Jänne, Kyriakos P. Papadopoulos, Piro Lito, Sai-Hong Ignatius Ou, Melissa L. Johnson, Igor I. Rybkin, Matthew A. Marx, Douglas P. Cassidy, Emanuel F. Patricoin, Elisa Baldelli, Mariaelena Pierobon, Jeremy Barton, Richard C. Chao, Karen Velastagui, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Yaohua Xue, Guy P. Vigers, John P. Fischer, Jay B. Fell, Michael R. Burkard, Joshua A. Ballard, Brian R. Baer, Vickie Bowcut, Niranjan Sudhakar, David M. Briere, Ruth Aranda, Andrew Calinisan, Lauren Hargis, Lars D. Engstrom, Jill Hallin
Supplementary Composite Figure File
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::095624453d8ad8530fb345958c4cd8b6
https://doi.org/10.1158/2159-8290.22535530.v1
https://doi.org/10.1158/2159-8290.22535530.v1
Autor:
Peter Olson, James G. Christensen, Kwok-Kin Wong, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Jill Hallin, Lars D. Engstrom, Jiehui Deng, David H. Peng, Lauren Hargis, Ruth Aranda, Niranjan Sudhakar, Andrew Calinisan, Shuai Li, David M. Briere
KRASG12C inhibitors, including MRTX849, are promising treatment options for KRAS-mutant non–small cell lung cancer (NSCLC). PD-1 inhibitors are approved in NSCLC; however, strategies to enhance checkpoint inhibitor therapy (CIT) are needed. KRASG12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0679ee9794421d5e87ada96097d171a6
https://doi.org/10.1158/1535-7163.c.6543400.v1
https://doi.org/10.1158/1535-7163.c.6543400.v1
Autor:
Peter Olson, James G. Christensen, Kwok-Kin Wong, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Jill Hallin, Lars D. Engstrom, Jiehui Deng, David H. Peng, Lauren Hargis, Ruth Aranda, Niranjan Sudhakar, Andrew Calinisan, Shuai Li, David M. Briere
Figures S1-S7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ceca5b28312dd8892d9b8d8ba17873c
https://doi.org/10.1158/1535-7163.22522492
https://doi.org/10.1158/1535-7163.22522492
Autor:
James G. Christensen, Peter Olson, Pasi A. Jänne, Kyriakos P. Papadopoulos, Piro Lito, Sai-Hong Ignatius Ou, Melissa L. Johnson, Igor I. Rybkin, Matthew A. Marx, Douglas P. Cassidy, Emanuel F. Patricoin, Elisa Baldelli, Mariaelena Pierobon, Jeremy Barton, Richard C. Chao, Karen Velastagui, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Yaohua Xue, Guy P. Vigers, John P. Fischer, Jay B. Fell, Michael R. Burkard, Joshua A. Ballard, Brian R. Baer, Vickie Bowcut, Niranjan Sudhakar, David M. Briere, Ruth Aranda, Andrew Calinisan, Lauren Hargis, Lars D. Engstrom, Jill Hallin
Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd866fa6fe03bc0849986ce88d5870c4
https://doi.org/10.1158/2159-8290.c.6547879.v1
https://doi.org/10.1158/2159-8290.c.6547879.v1
Autor:
Peter Olson, James G. Christensen, Kwok-Kin Wong, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Jill Hallin, Lars D. Engstrom, Jiehui Deng, David H. Peng, Lauren Hargis, Ruth Aranda, Niranjan Sudhakar, Andrew Calinisan, Shuai Li, David M. Briere
Supplementary Material
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89313461352dbe1920a2daf9ea2d10c3
https://doi.org/10.1158/1535-7163.22522489
https://doi.org/10.1158/1535-7163.22522489
Autor:
Laura Waters, Ruth Aranda, Krystal Moya, Victoria Bowcut, David Trinh, Allan Hebbert, Leo He, Laura D. Hover, Julio Fernandez-Banet, Jill Hallin, David M. Briere, James G. Christensen, Peter A. Olson, Lars D. Engstrom
Publikováno v:
Cancer Research. 83:2779-2779
Previous studies identified PRMT5 as a synthetic lethal target for cancers harboring homozygous deletion of the MTAP gene (MTAP del) whereby accumulation of MTA, the MTAP substrate, partially inhibits PRMT5 activity leading to an increased dependency
Autor:
Jill, Hallin, Vickie, Bowcut, Andrew, Calinisan, David M, Briere, Lauren, Hargis, Lars D, Engstrom, Jade, Laguer, James, Medwid, Darin, Vanderpool, Ella, Lifset, David, Trinh, Natalie, Hoffman, Xiaolun, Wang, J, David Lawson, Robin J, Gunn, Christopher R, Smith, Nicole C, Thomas, Matthew, Martinson, Alex, Bergstrom, Francis, Sullivan, Karyn, Bouhana, Shannon, Winski, Leo, He, Julio, Fernandez-Banet, Adam, Pavlicek, Jacob R, Haling, Lisa, Rahbaek, Matthew A, Marx, Peter, Olson, James G, Christensen
Publikováno v:
Nature medicine. 28(10)
Recent progress in targeting KRAS
Autor:
Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis, Lars D. Engstrom, Jade Laguer, Darin Vanderpool, Xiaolun Wang, J David Lawson, Nicole Thomas, Robin Gunn, Christopher R. Smith, Julio Fernandez-Banet, Leo He, Adam Pavlicek, Lisa Rahbaek, Matthew A. Marx, Peter Olson, James G. Christensen, Jill Hallin
Publikováno v:
Cancer Research. 82:1131-1131
The ability to effectively target mutated KRAS has remained elusive despite decades of research. Recently, the identification of selective KRASG12C inhibitors has provided an effective treatment option for patients harboring this particular mutation